טוען...

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

INTRODUCTION: The PACS01 trial has demonstrated that a docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC). We searched for prognostic and predictive markers for docetaxel's benefit....

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Jacquemier, Jocelyne, Boher, Jean-Marie, Roche, Henri, Esterni, Benjamin, Serin, Daniel, Kerbrat, Pierre, Andre, Fabrice, Finetti, Pascal, Charafe-Jauffret, Emmanuelle, Martin, Anne-Laure, Campone, Mario, Viens, Patrice, Birnbaum, Daniel, Penault-Llorca, Frédérique, Bertucci, François
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2011
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3326551/
https://ncbi.nlm.nih.gov/pubmed/22044691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3051
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!